ArticleFrontiers in immunology2025
Small extracellular vesicles from human umbilical cord mesenchymal stem cells delivering miR-202-5p alleviate renal ischemia-reperfusion injury by targeting the GOLIM4/PI3K/AKT axis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Functional Role of ALKBH5 in Kidney Injury: Insights Into Mechanisms and Therapeutic Potential.Journal of cellular biochemistry · 2026Review
- Extracellular vesicles mediate immune regulation in acute kidney injury.Frontiers in immunology · 2026Review
- Umbilical Cord Mesenchymal Stromal Cell-Derived Extracellular Vesicles Transfer CD59 to Astrocytes to Alleviate Complement-Dependent Cytotoxicity.Molecular neurobiology · 2025Article
- Organ-Specific Extracellular Vesicles in the Treatment of Ischemic Acute Organ Injury: Mechanisms, Successes, and Prospects.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ischemia-reperfusion injury (IRI) is a leading contributor to acute kidney injury (AKI), resulting in severe renal dysfunction and increased mortality. Despite progress in medical research, effective therapies for IRI remain limited. Recently, small extracellular vesicles (sEVs) originating from human umbilical cord mesenchymal stem cells (HucMSC-sEVs) have gained attention as potential therapeutic agents for alleviating organ damage. This study aimed to investigate the protective effects of HucMSC-sEVs in renal IRI and explore the underlying mechanisms involved. Methods: HucMSC-sEVs were isolated from HucMSCs via differential ultracentrifugation. Their characteristics were analyzed via transmission electron microscopy (TEM), nanoFCM, and western blotting. The protective effects of HucMSC-sEVs on OGD/R-induced apoptosis in HK-2 cells were evaluated via western blotting and flow cytometric analysis. Additionally, to explore the molecular mechanisms, qRT-PCR, dual-luciferase reporter assays, and other techniques were employed to investigate the role of miR-202-5p in HucMSC-sEVs, with a focus on its ability to regulate the PI3K/AKT pathway through the targeting of GOLIM4. Finally, the therapeutic effects of HucMSC-sEVs were evaluated Results: The HucMSC-sEVs exhibited a characteristic biconcave circular morphology, with a particle size range of 60-100 nm and an average diameter of 79.8 nm. Western blotting confirmed the presence of sEV markers CD9 and TSG101, and HucMSC-sEVs were efficiently taken up by HK-2 cells. In the OGD/R model, HucMSC-sEVs significantly reduced apoptosis, attenuated the expression of BAX and CC3, and promoted the upregulation of BCL-2. Mechanistic studies revealed that HucMSC-sEVs deliver miR-202-5p, which targets GOLIM4 and activates the PI3K/AKT pathway, ultimately reducing renal tubular cell apoptosis. In the mouse IRI model, HucMSC-sEVs significantly alleviated kidney damage and reduced the serum creatinine and urea nitrogen levels. Conclusion: This study is the first to demonstrate the role of HucMSC-sEVs in attenuating renal IRI both
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.